SCHEMBL6233752

SCHEMBL6233752

COc1ccc(-c2nc(C(F)F)oc2-c2ccc(OCc3ccccc3)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
HTT P42858 3/20 0.50
NPSR1 Q6W5P4 2/20 0.50
ALDH1A1 P00352 2/20 0.50
PPARD Q03181 2/20 0.44
MAPT P10636 5/20 0.43
ENPP3 O14638 1/20 0.43
ENPP1 P22413 1/20 0.43
IKBKE Q14164 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
BCHE P06276 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
HSD17B10 Q99714 2/20 0.40
HPGD P15428 2/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538977 1.00 LMNA (0.50) LMNAHTTNPSR1ALDH1A1PPARD
SCHEMBL6538937 0.90 NPSR1 (0.51) LMNAHTTNPSR1ALDH1A1PPARD
SCHEMBL6539132 0.88 MEN1 (0.45) LMNAHTTNPSR1ALDH1A1PPARD
SCHEMBL6539285 0.86 L3MBTL1 (0.47) LMNAHTTNPSR1ALDH1A1PPARD
SCHEMBL6206651 0.86 NPSR1 (0.47) LMNAHTTNPSR1ALDH1A1PPARD
SCHEMBL6234858 0.84 NPSR1 (0.46) LMNAHTTNPSR1ALDH1A1PPARD
SCHEMBL6207736 0.83 NPSR1 (0.54) LMNAHTTNPSR1ALDH1A1PPARD
SCHEMBL6539039 0.83 NPSR1 (0.54) LMNAHTTNPSR1ALDH1A1PPARD
SCHEMBL6208499 0.82 NPSR1 (0.56) LMNAHTTNPSR1ALDH1A1PPARD
SCHEMBL6229912 0.82 PPARD (0.40) ALDH1A1PPARDMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583749-A1 OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE Astellas Pharma Inc. (JP) 2005-10-12 EP disclosed
US-20040157891-A1 Inhibitor of cox FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-12 US disclosed
WO-2004065374-A1 OXAZOLE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE ASTELLAS PHARMA INC. (JP) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157891-A1 Inhibitor of cox PTGS1, PTGS2, PTGES2 LMNA 2620/4885HTT 3783/4885NPSR1 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.